These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12519610)

  • 1. Celecoxib for rheumatoid arthritis.
    Garner S; Fidan D; Frankish R; Judd M; Shea B; Towheed T; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2002; (4):CD003831. PubMed ID: 12519610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WITHDRAWN: Celecoxib for rheumatoid arthritis.
    Garner SE; Fidan D; Frankish RR; Judd M; Shea B; Towheed T; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003831. PubMed ID: 28598564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rofecoxib for the treatment of rheumatoid arthritis.
    Garner S; Fidan D; Frankish R; Judd M; Towheed T; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2002; (2):CD003685. PubMed ID: 12076502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rofecoxib for the treatment of rheumatoid arthritis.
    Garner S; Fidan D; Frankish R; Judd M; Towheed T; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2002; (3):CD003685. PubMed ID: 12137705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rofecoxib for rheumatoid arthritis.
    Garner SE; Fidan DD; Frankish RR; Judd MG; Towheed TE; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD003685. PubMed ID: 15674912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rofecoxib for osteoarthritis.
    Garner SE; Fidan DD; Frankish R; Maxwell L
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD005115. PubMed ID: 15654705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib.
    Ashcroft DM; Chapman SR; Clark WK; Millson DS
    Ann Pharmacother; 2001; 35(7-8):829-34. PubMed ID: 11485128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
    Deeks JJ; Smith LA; Bradley MD
    BMJ; 2002 Sep; 325(7365):619. PubMed ID: 12242171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs.
    Niculescu L; Li C; Huang J; Mallen S
    Curr Med Res Opin; 2009 Mar; 25(3):729-40. PubMed ID: 19210159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
    Clemett D; Goa KL
    Drugs; 2000 Apr; 59(4):957-80. PubMed ID: 10804043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
    van Walsem A; Pandhi S; Nixon RM; Guyot P; Karabis A; Moore RA
    Arthritis Res Ther; 2015 Mar; 17(1):66. PubMed ID: 25879879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
    Grabosch SM; Shariff OM; Wulff JL; Helm CW
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD004121. PubMed ID: 24715225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.